The National Cancer Institute recognized the emerging role of molecular imaging with a three-year contract aimed at the development of agents to diagnose and treat cancer. The $2.8 million contract was awarded to Barnes Jewish Hospital and Washington
The National Cancer Institute recognized the emerging role of molecular imaging with a three-year contract aimed at the development of agents to diagnose and treat cancer. The $2.8 million contract was awarded to Barnes Jewish Hospital and Washington University School of Medicine in St. Louis. The development and testing of novel agents will be done in combination with advanced imaging systems. Academic researchers will collaborate with Philips Medical and Dow Chemical to create and evaluate contrast and therapeutic agents designed to seek out specific molecular targets. Kereos will develop and commercialize promising agents.
The contract includes the development of nuclear imaging technology and image analysis techniques aimed at enhancing image quality, as well as delivering quantitative information about disease. Specific goals include finding means for detecting and quantifying solid tumors noninvasively and earlier in their development by identifying sites in the body where new blood vessels are forming to feed tumors. The research will also seek therapeutic agents that can be administered directly to the site of growing tumors to disrupt angiogenesis and the means to assess the adequacy of treatment by quantifying the amount of therapy delivered to a tumor.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.